Polyarteritis Nodosa
Polyarteritis nodosa is a systemic vasculitis affecting mainly medium-sized arteries. As a research services provider that is committed to the progression of therapies directed toward rare diseases including polyarteritis nodosa, Protheragen offers proven and highly regarded one-stop service covering the entire drug development process. Providing a comprehensive range of solutions from diagnostics to therapies, we simplify the journey from the laboratory to the application.
Introduction to Polyarteritis Nodosa
Polyarteritis nodosa (panarteritis nodosa, as it is a systemic disease) is a necrotizing vasculitis that primarily involves medium vessels, but not solely; it can also affect small vessels. The visceral and muscular arteries and their branches are the most commonly involved vessels in the disease. Major complications are hemorrhagic and thrombotic events in the heart, brain, and kidney. The annual incidence of polyarteritis nodosa is 0-1.6 cases/million inhabitants in European countries and the prevalence is approximately 31 cases/million.
Fig.1 Critical messages regarding the therapy of polyarteritis nodosa. (Chung, S. A., et al., 2021)Pathogenesis of Polyarteritis Nodosa
Polyarteritis nodosa can be associated with viral infections, in particular, hepatitis B virus; however, it is idiopathic in the majority of cases. Dendritic cells and CD4+ lymphocytes in vascular inflammatory infiltrates indicate that an antigen-specific T-cell-driven immune reaction may also be involved in vascular inflammation in polyarteritis nodosa.
Fig.2 Various etiologies of polyarteritis nodosa. (Wolff, L., et al., 2023)Therapeutics Development for Polyarteritis Nodosa
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Naltrexone | Immune modulation with reduction of proinflammatory cytokine production then leads to an improvement in vascular inflammation. | Opioid receptors | NCT03482479 | Phase II |
| Azathioprine | Inhibition of purine synthesis leads to suppression of the immune system with a decrease in the proliferation of immune cells participating in vascular inflammation. | DNA | NCT00647166 | Phase III |
| Prednisone | Inhibiting immune activity and decreasing inflammation within vessel walls via potent anti-inflammatory and immunosuppressive actions. | GR | NCT00307671 | Phase IV |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
Through our cutting-edge technology and expertise, we efficiently and effectively speed up your drug development. Our specially trained staff is dedicated to helping you progress in your goals by delivering a robust diagnostic and therapeutic development platform and target-specific disease models tailor-made for successful research and development. This tailored approach means that your R&D will be backed by high-quality, impactful data and support.
Animal Model Development for Polyarteritis Nodosa
Animal models are important to the study of mechanisms in polyarteritis nodosa, and to the testing of new potential therapeutic agents in a controlled environment before going through other tests. To overcome the limitations of the existing problems, our company provides you with tailor-made polyarteritis nodosa animal model development services.
Streptozotocin-nicotinamide Induced Vasculitis
This model induces vasculitis resembling polyarteritis nodosa by administering streptozotocin and nicotinamide to animals, causing endothelial damage and vascular inflammation in medium-sized arteries.
Cyp1a1ren-2 Transgenic Animal Model Development
In this animal model, indole-3-carbinol administered to Cyp1a1ren-2 transgenic rats causes polyarteritis nodosa-like vasculitis as a result of hypertension and medium-sized artery inflammation.
With both detailed pharmacokinetic assessments and in-depth drug safety studies, we have all aspects of the preclinical phase covered. Collaborate with us to boost your drug discovery efforts. By customizing our services to fit your individual needs, Protheragen partners with you to make your drug development goals a reality. Get in touch with us to discuss how we can help advance therapies for polyarteritis nodosa.
References
- Wolff, Louis et al. "Polyarteritis Nodosa: Old Disease, New Etiologies." International journal of molecular sciences 24.23 (2023): 16668.
- Chung, Sharon A et al. "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa." Arthritis care & research 73.8 (2021): 1061-1070.
For research use only, not for clinical use.